United States

Major General James Gilman, M.D., to lead NIH Clinical Center

Monday, December 12, 2016

NIH Director Francis S. Collins, M.D., Ph.D., has announced the selection of Major General James K. Gilman, M.D., U.S. Army (Retired), as the inaugural chief executive officer of the NIH Clinical Center, the nation’s largest hospital devoted to clinical research. Dr. Gilman is expected to join in early January 2017.

[Read More]

Epizyme receives Fast Track for Tazemetostat in B-cell lymphoma

Tuesday, November 29, 2016

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, has announced advancements in the company’s clinical programs evaluating tazemetostat, its first-in-class EZH2 inhibitor. The FDA has granted tazemetostat Fast Track designation in patients with diffuse large B-cell lymphoma (DLBCL) with EZH2 activating mutations. Additionally, Epizyme is focusing its phase II registration-enabling study in adult patients with genetically-defined solid tumors on those cancers marked by loss of INI1, and has expanded enrollment in the epithelioid sarcoma cohort of the study based on encouraging early activity in this patient population.

[Read More]

Steven G. Zylstra named Executive of the Year

Tuesday, November 29, 2016

The Arizona Technology Council’s President and CEO Steven G. Zylstra has been named the Arizona Society of Association Executives (AzSAE) Executive of the Year. The highest recognition given to a chief staff executive by the AzSAE, Zylstra is being recognized for his commitment to his association, its members, his civic and community affairs, and the affiliate associations and organizations he serves.

[Read More]